GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (OTCPK:GLABF) » Definitions » LT-Debt-to-Total-Asset

GLABF (Gemina Laboratories) LT-Debt-to-Total-Asset : 0.13 (As of Oct. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Gemina Laboratories LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Gemina Laboratories's long-term debt to total assests ratio for the quarter that ended in Oct. 2024 was 0.13.

Gemina Laboratories's long-term debt to total assets ratio declined from Oct. 2023 (0.13) to Oct. 2024 (0.13). It may suggest that Gemina Laboratories is progressively becoming less dependent on debt to grow their business.


Gemina Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for Gemina Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories LT-Debt-to-Total-Asset Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24
LT-Debt-to-Total-Asset
0.02 - 0.11 0.14

Gemina Laboratories Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.14 0.13 0.02 0.13

Gemina Laboratories LT-Debt-to-Total-Asset Calculation

Gemina Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (A: Jan. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Jan. 2024 )/Total Assets (A: Jan. 2024 )
=0.153/1.085
=

Gemina Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Oct. 2024 is calculated as

LT Debt to Total Assets (Q: Oct. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Oct. 2024 )/Total Assets (Q: Oct. 2024 )
=0.146/1.112
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gemina Laboratories  (OTCPK:GLABF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Gemina Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Gemina Laboratories Business Description

Traded in Other Exchanges
Address
3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.